Background COVID-19 is an illness caused by severe acute respiratory syndrome coronavirus 2. Due to its rapid spread, in March 2020 the World Health Organization (WHO) declared pandemic. Since the outbreak of pandemic many governments, scientists, and institutions started to work on new vaccines and finding of new and repurposing drugs. Main body of the abstract Drug repurposing is an excellent option for discovery of already used drugs, effective against COVID-19, lowering the cost of production, and shortening the period of delivery, especially when preclinical safety studies have already been performed. There are many approved drugs that showed significant results against COVID-19, like ivermectin and hydrochloroquine, including alternative treatment options against COVID-19, utilizing herbal medicine. Short conclusion This article summarized 11 repurposing drugs, their positive and negative health implications, along with traditional herbal alternatives, that harvest strong potential in efficient treatments options against COVID-19, with small or no significant side effects. Out of 11 repurposing drugs, four drugs are in status of emergency approval, most of them being in phase IV clinical trials. The first repurposing drug approved for clinical usage is remdesivir, whereas chloroquine and hydrochloroquine approval for emergency use was revoked by FDA for COVID-19 treatment in June 2020.

Comparative genomic hybridization (CGH) is a powerful molecular cytogenetic approach for identifying chromosomal abnormalities. CGH allows researchers to scan whole genomes for changes in DNA copy numbers. Starting in 2004, the array CGH became an irreplaceable method for the detection of gene mutations in people with congenital and developmental abnormalities, such as intellectual disability, dysmorphic characteristics, developmental delay, or several congenital deformities without an obvious syndrome pattern. This review focuses on the evolution of array CGH technology and its use in molecular diagnostics and its advantages over older cytogenetic tools. This review further highlights special arrays developed in the past decade which detect small intragenic copy number changes as well as large DNA segments for the region of heterozygosity.